TXMD

SEC source: 0001387131-18-006362 · bernick-form4_111918.xml · nonDerivative · entry 3

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006362 · bernick-form4_111918.xml · derivative · entry 7

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 457,510

Underlying: Common Stock · 91,400 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006362 · bernick-form4_111918.xml · nonDerivative · entry 2

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,557,371

F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.665 to $4.88, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006362 · bernick-form4_111918.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · derivative · entry 8

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 774,255

Underlying: Common Stock · 129,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 4

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472,419

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.78 to $5.11, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 3

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,601,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · derivative · entry 7

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 903,255

Underlying: Common Stock · 129,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 2

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472,419

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.65 to $5.015, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006314 · milligan-form4_111418.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,601,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · derivative · entry 8

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 552,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 4

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.73 to $4.935, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 3

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · derivative · entry 7

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 644,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 2

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.63 to $4.87, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006220 · finizio-form4_111218.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · derivative · entry 8

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 548,100

Underlying: Common Stock · 91,400 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · nonDerivative · entry 4

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,557,371

F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.75 to $4.925, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · nonDerivative · entry 3

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · derivative · entry 7

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 640,310

Underlying: Common Stock · 91,400 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · nonDerivative · entry 2

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,557,371

F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.6 to $5.05, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006131 · bernick-form4_110818.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-006074 · cartwright-form4_110718.xml · derivative · entry 3

Cartwright Daniel A · CIK 0001532231 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 220,000

Underlying: Common Stock · 40,000 shares

Expires 2021-10-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-006074 · cartwright-form4_110718.xml · nonDerivative · entry 2

Cartwright Daniel A · CIK 0001532231 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.68 to $4.955, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-006074 · cartwright-form4_110718.xml · nonDerivative · entry 1

Cartwright Daniel A · CIK 0001532231 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · derivative · entry 8

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 736,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 4

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.0 to $5.42, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 3

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · derivative · entry 7

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 828,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 2

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.24 to $5.55, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005729 · finizio-form4_102518.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · derivative · entry 8

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,032,255

Underlying: Common Stock · 125,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 4

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472,419

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.18 to $5.535, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 3

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,597,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · derivative · entry 7

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,157,255

Underlying: Common Stock · 125,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 2

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,472,419

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.15 to $5.435, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005637 · milligan-form4_102318.xml · nonDerivative · entry 1

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,597,419

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · derivative · entry 8

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 731,710

Underlying: Common Stock · 91,400 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · nonDerivative · entry 4

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,557,371

F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.43 to $5.66, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · nonDerivative · entry 3

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · derivative · entry 7

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 823,110

Underlying: Common Stock · 91,400 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · nonDerivative · entry 2

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,557,371

F2 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.48 to $5.87, inclusive. The Reporting Person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005562 · bernick-form4_101818.xml · nonDerivative · entry 1

Bernick Brian · CIK 0001532233 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By BF Investment Enterprises, Ltd.

Disclosed balance after: 6,648,771

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The Reporting Person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · derivative · entry 8

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 920,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 4

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.37 to $5.67, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 3

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · derivative · entry 7

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,012,910

Underlying: Common Stock · 92,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 2

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,393,559

F1 · kind: The sales were made pursuant to the Reporting Person's 10b5-1 trading plan with respect to shares of Common Stock underlying options to purchase Common Stock that expire on or before January 1, 2019.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.4 to $5.75, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001387131-18-005451 · finizio-form4_101118.xml · nonDerivative · entry 1

Finizio Robert G · CIK 0001532235 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,485,559

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001387131-18-005414 · milligan-form4_100918.xml · derivative · entry 8

Milligan John C.K. IV · CIK 0001532230 · Director · President/Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,282,255

Underlying: Common Stock · 125,000 shares

Expires 2019-01-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.